University of Wollongong
Browse

File(s) not publicly available

Betahistine ameliorates olanzapine-induced weight gain through modulation of histaminergic, NPY and AMPK pathways

journal contribution
posted on 2024-11-16, 07:13 authored by Jiamei LianJiamei Lian, Xu-Feng HuangXu-Feng Huang, Nagesh PaiNagesh Pai, Chao DengChao Deng
Olanzapine is widely used to treat schizophrenia and other disorders, but causes adverse obesity and other metabolic side-effects. Both animal and clinical studies have shown that co-treatment with betahistine (a histaminergic H1 receptor agonist and H3 receptor antagonist) is effective for ameliorating olanzapine-induced weight gain/obesity. To reveal the mechanisms underlying these effects, this study investigated the effects of co-treatment of olanzapine and betahistine (O + B) on expressions of histaminergic H1 receptor (H1R), AMP-activated protein kinase (AMPK), neuropeptide Y (NPY), and proopiomelanocortin (POMC) in the hypothalamus associated with reducing olanzapine-induced weight gain. Olanzapine significantly upregulated the mRNA and protein expressions of H1R, while O + B co-treatment significantly downregulated the H1R levels, compared to the olanzapine-only treatment group. The NPY mRNA expression was significantly enhanced by olanzapine, but it was significantly reversed by O + B co-treatment. The hypothalamic H1R expression was positively correlated with total food intake, and NPY expression. Olanzapine also increased AMPKα activation measured by the AMPKα phosphorylation (pAMPKα)/AMPKα ratio compared with controls, whereas O + B co-treatment decreased the pAMPKα/AMPKα ratio, compared with olanzapine only treatment. The pAMPKα/AMPKα ratio was positively correlated with total food intake and H1R expression. Although olanzapine administration decreased the POMC mRNA level, this level was not affected by O + B co-treatment. Therefore, these results suggested that co-treatment with betahistine may reverse olanzapine-induced body weight gain via the H1R-NPY and H1R-pAMPKα pathways.

Funding

Schizophrenia: Reversal of atypical antipsychotic drug-induced obesity and its related metabolic disorders

National Health and Medical Research Council

Find out more...

DECISION SUPPORT FOR CLIMATE CHANGE ADAPTATION IN CALIFORNIA'S MONTANE ECOSYSTEMS

National Institute of Food and Agriculture

Find out more...

History

Citation

Lian, J., Huang, X., Pai, N. & Deng, C. (2014). Betahistine ameliorates olanzapine-induced weight gain through modulation of histaminergic, NPY and AMPK pathways. Psychoneuroendocrinology, 48 77-86.

Journal title

Psychoneuroendocrinology

Volume

48

Pagination

77-86

Language

English

RIS ID

92204

Usage metrics

    Categories

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC